SUVENPHAR.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 13:00):

Stats
Šios dienos apimtis	122 136
Vidutinė apimtis	507 623
Rinkos kapitalizacija	167.94B
EPS	INR0 ( 2024-02-05 )
Kita pelno data	( INR0 ) 2024-05-22
Last Dividend	INR5.00 ( 2022-09-09 )
Next Dividend	INR0 ( N/A )
P/E	45.25
ATR14	INR0.616 (0.09%)

Tūris Koreliacija

Ilgas: -0.44 (neutral)

Trumpas: 0.59 (weak)

Signal:(22.642) Neutral

Suven Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Suven Pharmaceuticals Koreliacija - Valiuta/Žaliavos

-0.26
( neutral )

-0.14
( neutral )

0.46
( neutral )

-0.18
( neutral )

0.30
( neutral )

-0.35
( neutral )

Suven Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	INR13.40B
Bruto pelnas:	INR7.55B (56.32 %)
EPS:	INR16.16

FY	2022
Pajamos:	INR13.40B
Bruto pelnas:	INR7.55B (56.32 %)
EPS:	INR16.16

FY	2022
Pajamos:	INR12.90B
Bruto pelnas:	INR7.35B (56.96 %)
EPS:	INR17.83

FY	2021
Pajamos:	INR9.80B
Bruto pelnas:	INR5.60B (57.12 %)
EPS:	INR14.23

Financial Reports:

No articles found.

Suven Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Suven Pharmaceuticals Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 2.51 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR1.000	2021-02-17
Last Dividend	INR5.00	2022-09-09
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	INR10.00	--
Avg. Dividend % Per Year	0.37%	--
Score	3.37	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	2.51
Div. Directional Score	7.25	--

Next Divdend (Est)
(2024-07-22)

INR0 Estimate 0.00 %

Dividend Stability

0.11 Bad

Dividend Score

3.37

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2021	INR2.00	0.43%
2022	INR8.00	1.62%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SARDAEN.NS	Dividend Junior	2023-09-07	Annually	15	0.65%
MAGADSUGAR.NS	Dividend Junior	2023-07-13	Annually	7	1.78%
GMDCLTD.NS	Dividend Knight	2023-09-22	Annually	23	3.41%
ASTRAMICRO.NS	Dividend Junior	2023-08-23	Annually	20	0.49%
TITAN.NS	Dividend Junior	2023-07-13	Annually	20	0.35%
PETRONET.NS	Dividend Knight	2023-08-18	Semi-Annually	18	2.36%
JASH.NS	Dividend Junior	2023-09-22	Annually	7	0.57%
DBOL.NS	Dividend Junior	2023-06-23	Insufficient data to determine frequency	2	0.56%
SILINV.NS	Dividend Junior	2023-08-18	Annually	23	0.63%
MBAPL.NS	Dividend Junior	2023-09-18	Annually	8	0.44%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.318	1.500	3.65	5.47	[0 - 0.5]
returnOnAssetsTTM	0.180	1.200	3.99	4.79	[0 - 0.3]
returnOnEquityTTM	0.201	1.500	8.88	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	26.98	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	20.95	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	17.94	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0168	-1.500	9.72	-10.00	[0 - 0.6]
interestCoverageTTM	94.82	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	3.86	2.00	8.71	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.86	2.00	8.07	10.00	[0 - 20]
debtEquityRatioTTM	0.0174	-1.500	9.93	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.587	1.000	3.55	3.55	[0.2 - 0.8]
operatingProfitMarginTTM	0.424	1.000	3.51	3.51	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.85	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.567	0.800	9.55	7.64	[0.5 - 2]
Total Score				12.00

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	45.28	1.000	5.53	0	[1 - 100]
returnOnEquityTTM	0.201	2.50	9.28	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.86	2.00	8.71	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.86	2.00	8.71	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-4.83	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0842	1.000	-0.396	0	[0.1 - 0.5]
Total Score				2.51

Suven Pharmaceuticals

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was incorporated in 2018 and is headquartered in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.